文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

18F-BMS986192 PET显像PD-L1在免疫检查点抑制剂治疗的转移性黑色素瘤脑转移患者中的初步研究

18F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study.
PubMed 文献 · J Nucl Med · 2021-09-09

本初步研究对转移性黑色素瘤患者行18F-BMS986192 PET/CT显像以评估PD-L1表达,探索转移灶示踪剂摄取的变异性及其与肿瘤反应的关系,重点关注脑转移。基线示踪剂摄取与病灶直径变化负相关(r=-0.49,P=0.005),可区分应答与非应答病灶(AUC=0.82),随访扫描可检测治疗相关毒性。

要点

  • 基线18F-BMS986192摄取可预测ICI治疗所致病灶缩小。
  • 随访PET扫描可检测ICI相关毒性如甲状腺炎和结肠炎。
  • 肿瘤病灶示踪剂摄取异质性,脑内外病灶摄取相似。

核心结论

  • 18F-BMS986192 PET在黑色素瘤脑内外转移灶中显示异质性摄取,基线摄取可预测ICI治疗诱导的病灶体积缩小,随访扫描可检测治疗相关毒性。

研究设计与样本

  • 初步研究,转移性黑色素瘤患者接受ICI治疗前和开始治疗后6周行全身18F-BMS986192 PET/CT扫描,12周时用胸部/腹部CT和脑MRI评估肿瘤反应。

主要发现

  • 基线共识别42个肿瘤病灶,多数位于肺(n=21)和脑(n=14),肿瘤位置间示踪剂摄取相似。
  • 基线病灶18F-BMS986192摄取(经血池活性校正)与反应评估时病灶直径变化负相关(r=-0.49,P=0.005),脑内外病灶均如此。
  • ROC分析显示18F-BMS986192摄取可区分应答与非应答病灶,曲线下面积为0.82。
  • 随访扫描中,18F-BMS986192摄取较基线增加与反应评估时病灶直径增加相关。
  • 2例患者随访18F-BMS986192 PET扫描检测到ICI相关毒性(甲状腺炎和结肠炎)。

关键数值与推荐

  • 肿瘤反应按RECIST版本1.1定义患者水平应答,病灶水平应答用病灶直径百分比变化衡量。
  • 毒性按常见不良事件评价标准版本4.0评估。

临床怎么用

  • 18F-BMS986192 PET可能用于预测黑色素瘤患者ICI治疗反应,尤其是脑转移病灶。
  • 随访18F-BMS986192 PET可辅助检测ICI治疗相关毒性。

局限性

  • 初步研究,基线显像8例患者,仅4例有随访扫描。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) frequently induces tumor response in metastatic melanoma patients. However, tumor response often takes months and may be heterogeneous. Consequently, additional local treatment for nonresponsive metastases may be needed, especially in the case of brain metastases. Noninvasive imaging may allow the characterization of (brain) metastases to predict response. This pilot study uses 18F-BMS986192 PET for PD-L1 expression to explore the variability in metastatic tracer uptake and its relation to tumor response, with a special focus on brain metastases. Methods: Metastatic melanoma patients underwent whole-body 18F-BMS986192 PET/CT scanning before and 6 wk after starting ICI therapy. 18F-BMS986192 uptake was measured in healthy tissues, organs, and tumor lesions. Tumor response was evaluated at 12 wk using CT of the thorax/abdomen and MRI of the brain. RECIST, version 1.1, was used to define therapy response per patient. Response per lesion was measured by the percentage change in lesion diameter. Toxicity was assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results: Baseline 18F-BMS986192 PET/CT was performed in 8 patients, with follow-up scans in 4 patients. The highest tracer uptake was observed in the spleen, bone marrow, kidneys, and liver. Tracer uptake in tumor lesions was heterogeneous. In total, 42 tumor lesions were identified at baseline, with most lesions in the lungs (n = 21) and brain (n = 14). Tracer uptake was similar between tumor locations. 18F-BMS986192 uptake in lesions at baseline, corrected for blood-pool activity, was negatively correlated with the change lesion diameter at response evaluation (r = -0.49, P = 0.005), both in intra- and extracerebral lesions. Receiver-operating-characteristic analysis demonstrated that 18F-BMS986192 uptake can discriminate between responding and nonresponding lesions with an area under the curve of 0.82. At the follow-up scan, an increased 18F-BMS986192 uptake compared with baseline scan was correlated with an increased lesion diameter at response evaluation. In the follow-up 18F-BMS986192 PET scan of 2 patients, ICI-related toxicity (thyroiditis and colitis) was detected. Conclusion: In this pilot study, 18F-BMS986192 PET showed heterogeneous uptake in intra- and extracerebral metastatic lesions in melanoma patients. Baseline 18F-BMS986192 uptake was able to predict an ICI treatment-induced reduction in lesion volume, whereas the follow-up PET scan allowed the detection of treatment-induced toxicity.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nienhuis PH, Antunes IF, Glaudemans AWJM, et al. 18F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study. J Nucl Med. 2021. PMID: 34503964. doi:10.2967/jnumed.121.262368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。